Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma

Lymphoma Clinical Trial

Official title:

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma: a Single-arm, Open-label Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05320081
• Other study ID #: MA-ML-?-001
• Status: Recruiting
• Phase: Phase 2
• Start date: November 30, 2021
• Est. completion date: June 30, 2024

Study information

• Verified date: April 2022
• Source: Huazhong University of Science and Technology
• Contact: Jianfeng Zhou, MD, PhD
• Phone: 86-13627284963
• Email: jfzhou[@]tjh.tjmu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The is a phase II, single-arm, open-label clinical study assessing the efficacy and safety of Camrelizumab combined with CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 30 subjects with r/r CD30+ lymphoma。

Description:

This study intends to combine CD30 CAR-T (provided by Wuhan Bio-Raid Biotechnology Co., Ltd) and Camrelizumab (provided by Jiangsu Hengrui Pharmaceutical Co., Ltd.) to treat r/r CD30+ lymphoma, to observe the safety and effectiveness of the combined treatment, and to study the effect of PD-1 antibody on the pharmacokinetics and pharmacodynamics of CAR-T. Obtain a better treatment plan and provide a new strategy for the treatment of clinically r/r CD30+ lymphoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: June 30, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• age=18 years and =70 years,female and male;

• ECOG performance status 0-2;

• Histological or flow cytometry confirmed CD30+ lymphoma [according to WHO2008 diagnostic standard]

• Patients with CD30+ lymphoma relapsed after =2 lines of systemic treatment (the disease progresses after treatment remission) or refractory ( failed to obtain CR after previous systemic treatment);

• The patient did not receive any chemotherapy, radiotherapy, immunotherapy (such as immunosuppressive drugs) and other anti-cancer treatments within 4 weeks before enrollment, and the treatment-related toxicity has recovered to = Grade 1 (except for alopecia) 4 weeks before enrollment;

• At least 1 evaluable or measurable lesion can be measured according to the LYRIC 2016 evaluation criteria for malignant lymphoma ;

• Sufficient organ and bone marrow function, no serious abnormalities neither in hematopoietic function nor in heart, lung, liver, and kidney functions, and no immune deficiencies;

1. The absolute value of neutrophils is =1.5×109/L (for patients with bone marrow invasion =1.0×109/L);

2. Platelets =75×109/L (patients with bone marrow invasion =50×109/L);

3. Hemoglobin =9 g/dL;

4. Serum creatinine = 1.5× the upper limit of normal (ULN), or creatinine clearance =40 mL/min (estimated based on the Cockcroft-Gault formula);

5. Serum total bilirubin = 1.5 × ULN or = 3 × ULN ( liver invasion);.

6. f) Aspartate aminotransferase?Alanine Aminotransferase (ALT) =2.5 × ULN or =5 × ULN ( liver invasion);

7. Coagulation function: International Normalized Ratio (INR) = 1.5 × ULN; Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) = 1.5 × ULN (the PT and APTT should be within the expected range of anticoagulant therapy at the time of screening if the subject is receiving anticoagulant therapy,).

8. Thyroid-stimulating hormone (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) are within ±10% of the normal value.

9. Left ventricular ejection fraction (LVEF) = 50%, no serious malignant arrhythmia;

• The estimated survival time =6 months;

• Sufficient understanding and voluntarily to sign the informed consent form;

• Patients with fertility must be willing to be able to use reliable contraceptive measures during the clinical study and within 12 months after the last administration

Exclusion Criteria:

• Lymphoma associated hemophagocytic syndrome;

• Patients diagnosed as primary cutaneous anaplastic large cell lymphoma (ALCL) (patients can be enrolled if ALCL is transformed from other organ involvement);

• Patients with malignant T cells involving bone marrow or peripheral blood;

• Suffered from other malignant tumors in the past 5 years, except for for skin basal cell carcinoma, skin squamous cell carcinoma, breast carcinoma in situ and cervical carcinoma in situ undergoing the radical treatment

• Received CAR-T therapy or other genetically modified cell therapy before screening

• Received other treatments that affect the collection of T cells for when enrolled or within 4 weeks before enrollment;

• Suffer from active autoimmune diseases that require systemic treatment in the past two years (hormone replacement therapy is not considered as systemic treatment, such as type I diabetes, hypothyroidism that requires only thyroxine replacement therapy, patients with low adrenal function or hypopituitarism who need only physiological doses of glucocorticoid replacement therapy);

• Patients with uncontrolled infectious diseases, active viral hepatitis, tuberculosis, and HIV-infected ;

• Known to be allergic to ampicillin, antibodies, cytokines, anti-PD-1/PD-L1 antibodies or pharmaceutical excipients; or have severe allergic reactions to other monoclonal antibodies;

• Previous use of immunosuppressive drugs within 14 days before the first use of the drug, excluding nasal sprays and inhaled corticosteroids or physiological doses of systemic steroid hormones (ie not more than 10 mg/day prednisolone or equivalent physiological doses of other corticosteroids);

• long-term use of systemic hormones (dose equivalent to >10mg prednisone/day) or any other form of immunosuppressive therapy is required. Subjects using inhaled or topical corticosteroids can be enrolled;

• Suffer from uncontrolled comorbidities, including but not limited to symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, active peptic ulcer or bleeding disorders.

• With history of interstitial lung disease or non-infectious pneumonia. Subjects who have previously had drug-induced or radioactive non-infectious pneumonia but asymptomatic are allowed to enroll.

• Patients have other conditions that are not suitable for enrollment according to the judgment of the investigator.

Related Conditions & MeSH terms

• Lymphoma
• Recurrence
• Relapse/Recurrence

Intervention

Biological:
• CD30 CAR-T
Subjects need to complete a series of checks before reinfusion of CD30 CAR-T cells as baseline information for subjects after non-myeloablative pretreatment. The subject was reinfused with CD30 CAR-T cells (10±3)×10^6/kg on the 0th day of the first dosing cycle (the investigator decided the specific reinfusion dose based on the subject's own/disease conditions and preparation conditions in vitro ), concurrent oxygen inhalation and monitoring (ECG, blood pressure and blood oxygen monitoring). The reinfusion was completed in about 30 minutes, and the tube was flushed with saline. Note: CAR-T cell infusion and reinfusion dose are based on the subject's condition.

Drug:
• Camrelizumab
Received Camrelizumab treatment on the 15th day after CAR-T cell reinfusion, and then received Camrelizumab treatment every 2 weeks.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Nanchang University	Nanchang	Jiangxi
China	Department of Hematology Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (2)

Lead Sponsor	Collaborator
Huazhong University of Science and Technology	The First Affiliated Hospital of Nanchang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The copy number of CD30 CAR-T cells	The copy number of CD30 CAR-T cells amplified (copies/mcgDNA) in peripheral blood after administration;	12 months
Primary	overall response rate	including complete remission (CR) or partial remission (PR)	up to 3 months after CAR-T cell infusion
Primary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	To evaluate the safety of camrelizumab combined with CD30 CAR-T in the treatment of relapsed/refractory CD30+ lymphoma.	up to 90 days
Secondary	overall survival (OS)	The time from the day of enrollment to death due to any cause. If it is unclear whether the subject has died, OS refers to the duration from the day of enrollment to the date of the last follow-up.	24 months
Secondary	Duration of remission (DOR)	Defined as the time between the initial appearance of complete or partial remission for a subject in objective remission to the appearance of disease recurrence or death from any cause (whichever occurs first).	24 months
Secondary	Progression-free Survival (PFS)	The time from the start of the trial to the day of PD or to death due to any reason. If the subject's disease status is unclear, PFS refers to the duration from the day of enrollment to the date of the last follow-up.	24 months
Secondary	Time to Remission (TTR).	The time from the first day of medication to the first assessment of PR or CR, whichever comes first. Only applicable to subjects with CR or PR.	12 months